Thottea siliquosa
Thottea siliquosa · Accepted scientific name
Scientific literature: Very Sparse (0 studies) · ★☆☆☆☆
Thottea siliquosa is a botanical species currently being investigated for its significant therapeutic potential in medical research. Scientific studies have focused specifically on the aqueous root extract of this plant to evaluate its biological activity. Preliminary chemical analysis reveals the presence of important compounds such as 2-Palmitoylglycerol, Isocorydine, Thunbergol, and squalene. These bioactive constituents are of particular interest due to their documented effects under specific pathological conditions. Consequently, research is heavily centered on the plant's ability to influence processes related to cancer.
- Synonyms
- Apama Siliquosa · Bragantia Wallichii · 5 more
- Common names
- Not available
- Family
- Aristolochiaceae
- Distribution
- Not available
- Plant Parts
- Root
Classification
Synonyms
Thottea siliquosa is a plant species characterized by a complex history of botanical nomenclature. Throughout various taxonomic studies, it has been identified by several different scientific names. For instance, it is recognized by the synonyms Apama laurifolia and Apama siliquosa. The species also shares synonyms with the Bragantia genus, specifically under the names Bragantia hispida and Bragantia wallichii. Additionally, the botanical record includes the specific variety Bragantia wallichii var. brachycarpa as a synonym for this plant.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Thottea siliquosa belongs to the vast kingdom Plantae, marking its place among the diverse life forms of the natural world. Within this kingdom, it is classified under the class Equisetopsida and follows the specific biological order of Piperales. This plant is further distinguished as a member of the Aristolochiaceae family. Its taxonomic identity is defined by its placement within the genus Thottea. Through these systematic relationships, scientists can better understand its unique evolutionary history.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Piperales |
| Family | Aristolochiaceae |
| Genus | Thottea |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Thottea siliquosa is a distinctive plant species primarily found within the lush environments of the Asia-Tropical region. Its natural range spans across the Indian Subcontinent, making it a notable part of the local flora. Within this vast area, the species is well-documented throughout various parts of India. Additionally, its distribution extends to the island nation of Sri Lanka, where it thrives in specific habitats. This widespread presence underscores the importance of the plant within these diverse tropical ecosystems.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Thottea siliquosa is characterized by an obligatory climbing habit, meaning it relies fundamentally on surrounding structures for support to reach the light.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Compounds
Thottea siliquosa contains a diverse array of bioactive compounds that demonstrate significant potential in cancer research. Phytochemical profiling of its root extract has identified key constituents such as isocorydine and thunbergol, both of which exhibit strong binding affinities for CDK4 and CDK6. Additionally, the plant contains squalene and 2-palmitoylglycerol, which contribute to its multi-targeted pharmacological profile. These specific phytochemicals work through synergistic interactions to provide anti-proliferative effects against cancer cells. Ultimately, the presence of these compounds positions the plant as a promising candidate for developing natural, plant-based therapeutic interventions.
Conditions
Thottea siliquosa root extract demonstrates significant potential in treating cancer by acting as a natural inhibitor of cyclin-dependent kinases 4 and 6. Research indicates that bioactive compounds within the plant, such as Isocorydine and Thunbergol, exhibit binding affinities for CDK4/6 that are comparable to standard clinical inhibitors. By targeting these pivotal cell cycle regulators, the plant extract serves as a promising therapeutic candidate specifically for CDK4/6-associated cancers. In vitro assays have confirmed this relationship, showing dose-dependent cytotoxicity and reduced cell migration in HCT116 cancer cells. These findings highlight the ability of Thottea siliquosa to exert anti-proliferative effects through its unique phytochemical interactions.
Preparations
Thottea siliquosa is prepared as an aqueous root extract to evaluate its medicinal potential. This specific preparation method allows researchers to identify bioactive compounds like Isocorydine and Thunbergol through phytochemical profiling. By using an aqueous extraction process, the study aims to harness the plant's natural ability to inhibit CDK4/6 regulators. The resulting extract serves as a concentrated source for testing anti-proliferative effects against cancer cells. Consequently, the aqueous root extract of this plant is being investigated as a promising candidate for plant-based cancer therapeutics.
Parts used
Thottea siliquosa is a traditionally used medicinal plant that holds significant potential for modern oncological research. Recent studies have focused specifically on the aqueous extract derived from the plant's root to evaluate its therapeutic properties. Through GC-MS profiling, researchers identified several bioactive compounds within the root that interact effectively with cyclin-dependent kinases. Molecular docking results suggest that these root-derived constituents, such as Isocorydine and Thunbergol, exhibit binding affinities comparable to established synthetic inhibitors. Ultimately, the cytotoxic effects observed in the root extract highlight its promise as a multi-targeted, plant-based candidate for treating CDK4/6-associated cancers.